Compositions and methods for promoting the generation of definitive endoderm
Certain embodiments disclosed herein are directed to a method of producing endoderm cells, such as definitive endoderm cells by exposing stem cells such as embryonic stem cells or induced pluripotent stem (iPS) cells to an effective amount of at least one compound described herein to differentiate the stem cells into the endoderm cells such as definitive endoderm cells. Differentiated endoderm cells produced by the methods disclosed herein can be differentiated into pancreatic epithelium, and other endoderm derivatives such as thymus, liver, stomach, intestine and lung. Another aspect of the present invention relates to a method of producing pancreatic progenitor cells, such as Pdx1-positive pancreatic progenitor cells by exposing endoderm cells, such as definitive endoderm cells to an effective amount of at least one compound described herein to differentiate the definitive endoderm cells into Pdx1-positive pancreatic progenitor cells. Kits and compositions comprising Pdx1-positive pancreatic progenitor produced using the methods are also described.
1. A method comprising:
(a) contacting a population of pluripotent stem cells with at least one compound of Formula (I) that activates TGF-β signaling, thereby inducing the differentiation of at least one pluripotent stem cell into a definitive endoderm cell, wherein the definitive endoderm cell expresses Sox17, or HNF3B (FoxA2), or Sox17 and HNF3B (FoxA2) and wherein the compound of formula (I) is:
wherein:
R 1 and R 2 are independently H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, or cyclyl, each of which can be optionally substituted and/or can be interrupted in the backbone with one or more of O, N, S, S(O), and C(O);
R 3 and R 4 are independently H, halogen, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, cyclyl, or cyclyl, each of which can be optionally substituted, or R 3 and R 4 together with the carbon to which they are attached from an optionally substituted cyclyl or heterocyclyl; and
L is C 1 -C 10 alkylenyl, C 2 -C 10 alkenylenyl, or C 2 -C 10 alkynylenyl, each of which can be optionally substituted and/or can be interrupted in the backbone with one or more of O, N, S, S(O), and C(O), thereby producing a definitive endoderm cell from a pluripotent stem cell; and
(b) differentiating the definitive endoderm cell into a Pdx1-positive pancreatic progenitor cell, wherein the Pdx1-positive pancreatic progenitor cell expresses Pdx1.
2. The method of claim 1 , wherein a Pdx1-positive pancreatic progenitor cell also expresses HNF6.
3. The method of claim 1 , wherein (b) comprises contacting a population of definitive endoderm cells with at least one compound of Formula (II) to induce the differentiation of at least one definitive endoderm cell into a Pdx1-positive pancreatic progenitor cell, wherein the compound of formula (II) is:
wherein:
R 21 is H, alkyl, each of which can be optionally substituted;
R 22 and R 23 are independently H, OH, alkyl, alkoxy, or cyclyl, each of which can be optionally substituted; and
R 24 and R 25 are each independently H, OH, alkyl, alkoxy, or cyclyl, each of which can be optionally substituted, or R 24 and R 25 together with the carbons to which they are attached form an optionally substituted cyclyl.
4. The method of claim 3 , wherein the compound of Formula (II) is (2S,5S)-1,2,4,5,6,8-Hexahydro-5-(hydroxymethyl)-1-methyl-2-(1-methylethyl)-3H-pyrrolo[4,3,2-gh]-1,4-benzodiazonin-3-one ((−)-indolactam V).
5. The method of claim 3 , further comprising isolating a population of Pdx1-positive pancreatic progenitor cells.
6. The method of claim 5 , further comprising differentiating the population of Pdx1-positive pancreatic progenitor cells into a population of insulin producing cells.
7. The method of claim 5 , further comprising differentiating the population of Pdx1-positive pancreatic progenitor cells into a population of cells having at least one characteristic of endogenous pancreatic β-cells.
8. The method of claim 7 , wherein a cell with at least one characteristic of an endogenous pancreatic β-cell is secretion of insulin in response to glucose.
9. A method comprising contacting a population of definitive endoderm cells with at least one compound of Formula (II) to induce the differentiation of at least one definitive endoderm cell into a Pdx1-positive pancreatic progenitor cell, wherein the compound of formula (II) is:
wherein:
R 21 is H, alkyl, each of which can be optionally substituted;
R 22 and R 23 are independently H, OH, alkyl, alkoxy, each of which can be optionally substituted; and
R 24 and R 25 are each independently H, OH, alkyl, alkoxy, or cyclyl, each of which can be optionally substituted, or R 24 and R 25 together with the carbons to which they are attached form an optionally substituted cyclyl, thereby differentiating a definitive endoderm cell into a Pdx1-positive pancreatic progenitor cell.
10. The method of claim 9 , wherein the compound of Formula (II) is (2S,5S)-1,2,4,5,6,8-Hexahydro-5-(hydroxymethyl)-1-methyl-2-(1-methylethyl)-3H-pyrrolo[4,3,2-gh]1,4-benzodiazonin-3-one ((−)-indolactam V).
11. The method of claim 9 , further comprising isolating a population of Pdx1-positive pancreatic progenitor cells.
12. The method of claim 9 , wherein the Pdx1-positive pancreatic progenitor cell expresses Pdx1.
13. The method of claim 9 , wherein the Pdx1-positive pancreatic progenitor cell expresses HNF6.
14. The method of claim 9 , further comprising differentiating a population of Pdx1-positive pancreatic progenitor cells into a population of insulin producing cells.
15. The method of claim 9 , further comprising differentiating a population of Pdx1-positive pancreatic progenitor cells into a population of cells having at least one characteristic of endogenous pancreatic β-cells.
16. The method of claim 15 , wherein a cell with at least one characteristic of an endogenous pancreatic β-cell is secretion of insulin in response to glucose.